Kindred Biosciences (KIN) Tops Q4 EPS by 9c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.34), $0.09 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
• Enhanced Group Inc. (ENHA) Reports Q2 Loss of $0.53